Erasca, Inc. Common Stock ERAS
Analyst Ratings
- Consensus
- Buy — 7 Buy · 2 Hold · 0 Sell (9 analysts)
- Avg. Price Target
- $22.56 (+40.7% upside)
Key Stats
- Today's Range
- $15.21 – $16.20
- 50-Day Range
- $13.54 – $20.40
- 52-Week Range
- $1.47 – $24.28
- Volume
- 7.77 million shs
- Average Volume
- 5.04 million shs
- Market Cap
- $5.41 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.25%
- Days to Cover
- 1.00
About Erasca, Inc. Common Stock
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Related Stocks
Compare head-to-head: ERAS vs LLY·ERAS vs JNJ·ERAS vs ABBV·ERAS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.